The Valley Desk

ArticleCancersPublished

Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
Cancers
Published
Subject terms
Lung cancer; efficacy; Crizotinib; Entrectinib; Population-adjusted Indirect Comparisons; Ros1 Fusion-positive; Repotrectinib
PubMed ID
40075596
PubMed Central ID
PMC11899369
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal